HIV resistance to dolutegravir varies with co-administered agents.

Beck, Ingrid A; Boyce, Ceejay L; Bishop, Marley D; Oldroyd, Alyssa R; du Toit, Louise; Saimen, Amashnee; Ramarope, Kholofelo Mn; Hitchcock, Sonia et al. · Clin Infect Dis · 2025

retrospective_cohort · Level III

Where this comes from

Record sourced from PubMed, PMID 40898778.
Also identified by DOI 10.1093/cid/ciaf481.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

We hypothesized that HIV-dolutegravir-resistance is more frequent when co-administered with nucleos(t)ides with shorter intracellular half-lives. Multivariable analysis of 183 viremic (≥200c/mL) participants from four cohorts (N=660 participants) found dolutegravir-resistance in 21 (11.5%). Dolutegravir-resistance was greater with dolutegravir+lamivudine+zidovudine/(one on stavudine) (OR=19.4, 95%CI 5.1-74.3) or dolutegravir+lamivudine+abacavir (OR=5.4, 95%CI 1.1-25.8), compared to dolutegravir+lamivudine+tenofovir.

Read the full text

View on PubMed · Publisher (DOI)